Related Experiment Video
Updated: Jan 4, 2026
09:18
Efficient and Rapid Generation of CAR-T and Cytokine-Induced Killer Cells in GMP-scalable Devices
Published on: December 5, 2025
142
Platforms for Clinical-Grade CAR-T Cell Expansion.
Amanda Mizukami1, Kamilla Swiech2,3
1Center for Cell-Based Therapy CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. amanda.mizukami@hemocentro.fmrp.usp.br.
Methods in Molecular Biology (Clifton, N.J.)
|November 11, 2019
Summary
Chimeric antigen receptor (CAR)-T cell therapy offers promising cancer treatment. Optimizing cell expansion platforms is crucial for standardizing manufacturing and reducing costs for wider patient access.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Biotechnology
Background:
- Chimeric antigen receptor (CAR)-T cell therapy has transformed immunotherapy, achieving high complete response rates in hematological malignancies.
- CAR-T cell manufacturing involves T cell selection, activation, genetic modification, and in vitro expansion, requiring optimization of culture systems.
- Current clinical trials predominantly use flasks, bags, and rocking motion bioreactors for CAR-T cell expansion, lacking standardization.
Purpose of the Study:
- To review and evaluate various cell expansion platforms for CAR-T cell manufacturing.
- To highlight the need for standardization and automation in CAR-T cell production.
- To discuss quality control requirements for clinical-grade CAR-T cell products.
Main Methods:
- Review of existing literature on CAR-T cell expansion platforms.
- Analysis of current manufacturing processes and technologies.
- Discussion of quality control measures for clinical applications.
Main Results:
- Flasks, bags, and rocking motion bioreactors are common but non-standardized platforms for CAR-T cell expansion.
- Automation and standardization efforts are needed to increase production scale and reduce costs.
- Quality control is essential for ensuring the safety and efficacy of clinical-grade CAR-T cells.
Conclusions:
- Optimizing cell expansion platforms is critical for the efficient and standardized production of CAR-T cells.
- Advancements in automation and scale-up are necessary to lower costs and increase accessibility of CAR-T therapy.
- Adherence to stringent quality control measures is paramount for clinical-grade CAR-T cell production.
